[Microbiological studies on the combination effect of rifampicin and nalidixic acid (author's transl)].
D000818:Animals; D004269:DNA, Bacterial / Q000096:biosynthesis; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004754:Enterobacter / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae / Q000187:drug effects; D051379:Mice; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D011514:Proteus vulgaris / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012293:Rifampin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D012477:Salmonella enteritidis / Q000187:drug effects; D012485:Salmonella typhi / Q000187:drug effects; D012763:Shigella flexneri / Q000187:drug effects; D012764:Shigella sonnei / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects
D004269:DNA, Bacterial; D009268:Nalidixic Acid; D012293:Rifampin